43results about How to "Modulate effect" patented technology

A smart window includes a windowpane, at least one sensor and a wireless signal transceiver. The sensor is disposed on the windowpane and configured for detecting an environmental factor and accordingly outputting a sensing signal. The wireless signal transceiver is disposed on the windowpane and electrically connected to the sensor. The wireless signal transceiver is configured for further transmitting the sensing signal from the sensor. A smart window system includes the aforementioned smart window. The smart window and the smart window system adopt wireless communication manner to transmit the sensing signals, and thereby the smart window system has an overall modulation to an environmental factor.

The invention provides a method for preventing adverse effects associated with the use of a medical device in a patient by introducing into the patient a device of which at least a portion includes a prophylactic or therapeutic amount of a nitric oxide adduct. The nitric oxide adduct can be present in a matrix coating on a surface of the medical device; coated per se on a surface of the medical device; directly or indirectly bound to reactive sites on a surface of the medical device; or at least a portion of the medical device can be formed of a material, such as a polymer, which includes the nitric oxide adduct. Also disclosed is a method for preventing adverse effects associated with the use of a medical device in a patient by locally administering a nitric oxide adduct to the site of contact of said device with any internal tissue.

A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue.

Methods for modulating one or more side effects of 5-α-reductase inhibitor therapy are provided, where the method includes administering a 5-α-reductase inhibitor and testosterone undecanoate. Also provided are methods of maintaining or restoring a DHT serum level in an individual undergoing 5-α-reductase inhibitor therapy, where the method includes administering testosterone undecanoate in addition to 5-α-reductase inhibitor. Further provided are methods of treating or preventing a DHT-related condition, such as benign prostate hyperplasia (BPH) or prostate cancer by administering a 5-α-reductase inhibitor and testosterone undecanoate.

New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1) wherein X is N, CH, or C, however X may only be C when the compound comprises a double bind at the dotted line; R1 is CF3, OSO2CF3, OSO2CH3, SOR7, SO2R7, COR7, CN, OR3, NO2, CONHR3, 3-thiophene, 2-thiophene, 3-furane, 2-furane, F, Cl, Br, or I; R2 is F, Cl, Br, I, CN, CF3, CH3, OCH3, OH, and NH2; R3 and R4 are independently H or a C1-C4 alkyl; R5 is a C1-C4 alkyl, an allyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, or —(CH2)R6; R6 is a C3-C6 cycloalkyl, 2-tetrahydrofurane, or 3-tetra-hydrofurane; R7 is a C1-C3 alkyl, CF3, or N(R4)2, and pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed.

A pair of men s shorts, including under shorts, has a typical chassis with an abdomen opening, a right pant leg and a left pant leg. The user's genitals pass through an opening on the front of the chassis whenever the shorts are being worn. A hammock overlies the opening and is anchored to the chassis at two points on the right out seam, one point below the other, and two points on the left out seam, symmetrical with the right out seam attachment. The hammock is also attached to the chassis at the waist band and at the lower edge of the opening just above the left and right inseam joinder area. The hammock by being anchored at the out seams and being non-stretching in a transverse direction, acts as a sling in supporting the genitals of the user.

The invention concerns a lighting and / or signalling device for a motor vehicle comprising at least one light source emitting a light beam and at least one optical guide in which the light beam propagates, said optical guide comprising an output face for the light beam, and another reflection face, opposite to the output face, having a serrated profile forming a reflection face for the light beam, notably comprising a series of prisms, each prism forming, with the following prism (8), a bottom angle (D). At least one bottom angle of the reflection face is truncated, and / or in that the output face has a profile comprising flutes.

A composition is provided for modulating or attenuating the cytokine induced cell surface expression of cell adhesion molecules, comprising an antibody that binds digoxin. There is also provided a method of modulating or attenuating the cytokine induced cell surface expression of a cell adhesion molecule in a patient by administering to a digoxin antibody composition to a patient in need of such treatment.

A polarization rotator is provided for rotating the polarization direction of linearly polarized light by any arbitrary angle other than 90°. The device comprises a layer of liquid crystal material disposed between alignment surfaces. In one mode, a 90° twist is induced in the liquid crystal director. An expression is provided for relating the retardation of the layer to the amount of polarization rotation and the angle between the polarization direction of incident light and the alignment direction at the input side of the liquid crystal layer.

Compositions and methods for modulation of the suppressive activity of CD4+CD25+regulatory T cells (Treg) on CD4+CD25− effector T cells (Teff) are provided. An agent selected from: (i) dopamine; (ii) a dopamine precursor; (iii) a D1-R agonist; (iv) a D2-R antagonist; (v) a combination of (i) and (ii); or (vi) a combination of (i), (ii) or (iii) with (iv), down-regulates the suppressive activity of Treg and is useful for treatment of cancer. An agent selected from (i) a dopamine D2-R agonist, (ii) a dopamine D1-R antagonist, and (iii) a combination of (i) and (ii), up-regulates the suppressive activity of Treg and is useful for treatment of an autoimmune disease or for controlling graft rejection in tissue / organ transplantation.

The present invention provides a method of production and screening of small molecule modulation of inter-macromolecule interaction. The method involves providing a living cell containing a gene that directs expression of a gene product to be assayed for the ability to modulate inter-macromolecule interactions and an inter-macromolecule interaction whose interaction can be monitored. The inter-macromolecule interaction is monitored in the living cell to determine if the inter-macromolecule interaction is modulated in the living cell relative to another, otherwise similar living cell that lacks said gene product.

A system for modulating audio effects of speakers is provided. The system includes a selecting module, a playing module, a recording module, a time delay computing module and a modulating module. Based on these modules, the system is capable of determining a time difference and a pitch for each of the speakers, and modulating the time difference and the pitch for each of the speakers to a desired time difference and a desired pitch, so as to ensure that simultaneous sounds from each speaker arrive at a microphone at about the same time and with the same audio pitch. A related method is also provided.

A method (1300) of forming a semiconductor device comprising an isolation structure is disclosed, and includes forming a trench region within a semiconductor body (1308). Then, surfaces of the trench region are nitrided (1310) via a nitridation process. An oxidation process is performed that combines with the nitrided surfaces (1312) to form a nitrogen containing liner. Subsequently, the trench region is filled with dielectric material (1316) and then planarized (1318) to remove excess dielectric fill material.

This invention relates to polybacterial probiotic preparation, which includes new strains of lactic acid bacteria Lactobacillus gasseri 7 / 12 NBIMCC No. 8720, Lactobacillus plantarum F12 NBIMCC No 8722 and Lactobacillus helveticus A1, NBIMCC No 8721 and has the following set of properties: antioxidant, hypocholesterolemic effect, anti-inflammatory immunomodulating effect, ability to release bioactive peptides that inhibit angiotensin-converting enzyme (ACE), which is responsible for the high blood pressure. The object of invention is also the described probiotic strains of lactic acid bacteria and the developed bacterial products with useful properties. The incorporated probiotic strain Lactobacillus gasseri 7 / 12 NBIMCC No. 8720, has a number of properties: strong adhesion to the epithelial layer of the colon, the ability for reduction of cholesterol and anti-inflammatory effects by reducing the levels of proinflammatory cytokine interleukin-8. The invention relates to the use of strains of lactic acid bacteria and bacterial agents in the production of starter cultures, food additives, food, functional products and pharmaceutical preparations intended to influence the health of humans and animals.

This invention relates to a Fe-based catalyst for Fischer-Tropsch synthesis, preparation method and application thereof. The catalyst contains Fe, oxide(s) of IB group metal Cu and / or Ag as a reducing promoter, IA group metal Li, Na, K or Rb as an electron promoter, VIII group noble metal Ru, Rh, Pd or Pt as a hydrogenation promoter and SiO2 as a structure promoter. The preparation method comprises the following steps: preparing a solution of Fe salt; co-precipitating the solution rapidly with an alkaline compound, then washing and pulping again; and adding a solution of IB group metal salt as a reducing promoter, a IA group metal salt solution and silica sol, or adding a solution of IB group metal salt as a reducing promoter and a silicate of IA group metal; then molding by spray-drying, impregnating in a solution of VIII group noble metal salt, and drying and roasting to obtain the catalyst. The catalyst is suitable for producing hydrocarbons by a low temperature Fischer-Tropsch synthesis process. The process has a high yield of heavy hydrocarbons and a low selectivity to methane and significantly reduces the selectivity to olefins.

A charge multiplication amplifier device comprises a series arrangement of a first separation barrier facility, a temporary storage well for charge carriers, a second charge transfer barrier facility, an impact ionization facility that is operative through electric field strength effective on mobile charge carriers, and a charge collection well for receiving charge carriers so multiplied.Advantageously, the device comprises a charge collection and transfer facility (32) that is geometrically disposed next to the impact ionization facility (31) whereas impact ionization facility is controlled at a substantially static electric potential (DC1, DC2) for controlling the electric field strength.Advantageously, another embodiment of this device comprises charge collection and transfer facilities (41, 42) implemented as two (or more) independently clocked signals Φ1, Φ2 that require nearly two times less swing to achieve same effect.

The invention provides a method of evaluating the quality of an audiovisual sequence by:a) training, comprising allocating a subjective score NSi to each of N0 training sequences Si (where i=1, 2, . . . , N0) presenting degradations identified by a training vector MO1 which is given to each sequence Si in application of a first vectorizing method, in order to build up a database of N0 training vectors MOi with subjective scores NS1;b) classifying the N0 training vectors MOi into k classes of scores as a function of the subjective scores NS1 that have been allocated to them, so as to form k training sets EA (where j=1, 2, . . . , k) which have k significant training scores NSRj allocated thereto;c) for each audiovisual sequence to be evaluated, generating a vector MO using said first vectorization method; andd) allocating to the audiovisual sequence for evaluation the significant training score NSRj that corresponds to the closest training set EAj.

A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue. A synergistic composition comprises co-administration of theacrine and caffeine, wherein the co-administered caffeine reduces theacrine oral clearance (CL / F) and oral volume of distribution (Vd / F). In addition, the co-administered caffeine increases area under the plasma concentration time curve (AUC) of theacrine, and increases theacrine maximum plasma concentration (Cmax) in comparison with the corresponding pharmacokinetic parameters when theacrine is administered alone.

The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

A charge multiplication amplifier device comprises a series arrangement of a first separation barrier facility, a temporary storage well for charge carriers, a second charge transfer barrier facility, an impact ionization facility that is operative through electric field strength effective on mobile charge carriers, and a charge collection well for receiving charge carriers so multiplied.Advantageously, the device comprises a charge collection and transfer facility (32) that is geometrically disposed next to the impact ionization facility (31) whereas impact ionization facility is controlled at a substantially static electric potential (DC1, DC2) for controlling the electric field strength.Advantageously, another embodiment of this device comprises charge collection and transfer facilities (41, 42) implemented as two (or more) independently clocked signals Φ1, Φ2 that require nearly two times less swing to achieve same effect.

Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I):wherein: L represents a linker selected from —C≡C—, (a tolan), —CH═CH— (a stilbene, preferably trans); or —CRa═CRb— a stilbene derivative; where Ra and Rb are independently H or phenyl optionally substituted with —(R3)p or —(R4)q;R1 to R4 are independent substituents at any available position of the phenyl rings, preferably at 3, 3′, 4, 4′, and / or 5, 5′; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be ≧1. Each R1 to R2 is independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein. The formulation may include a hydrogel formed by the compounds themselves or otherwise and may include salts and / or complexes.

Compositions and methods are provided for modulating the activity of cells using engineered receptors, polynucleotide encoded engineered receptors, and gene therapy vectors comprising polynucleotides encoding engineered receptors. These compositions and methods find particular use in modulating the activity of neurons, for example in the treatment of disease or in the study of neuronal circuits.

The invention relates to a compound of formula (I):or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, and to a method for the treatment an acute or chronic inflammatory disease by inhibiting the production of at least one pro-inflammatory cytokine selected from TNF-alpha, IFN-gamma, IL-8 and IL-10, which comprises administering to a patient who needs such treatment a therapeutically effective amount of a compound of formula (I) as defined above.

The invention is a garment which has the characteristic of supporting the male genitals in a cradle created by a suspension of cloth which does not pull towards the abdomen, but rather is itself supported by anchoring points at the waistline at the maximum width of the torso. This forms a sling-like platform which functions much like a hammock stretched between two trees, and the wearer's genitals rest on the hammock. The structure necessary to support the hammock is a form-fitting athletic short, with certain modifications to support the improvement of the invention.

New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1) wherein X is N, CH, or C, however X may only be C when the compound comprises a double bind at the dotted line; R1 is CF3, OSO2CF3, OSO2CH3, SOR7, SO2R7, COR7, CN, OR3, NO2, CONHR3, 3-thiophene, 2-thiophene, 3-furane, 2-furane, F, Cl, Br, or I; R2 is F, Cl, Br, I, CN, CF3, CH3, OCH3, OH, and NH2; R3 and R4 are independently H or a C1-C4 alkyl; R5 is a C1-C4 alkyl, an allyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, or —(CH2)R6; R6 is a C3-C6 cycloalkyl, 2-tetrahydrofurane, or 3-tetra-hydrofurane; R7 is a C1-C3 alkyl, CF3, or N(R4)2, and pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed.

A compound for use in the treatment of itch is provided, wherein the composed comprises the general formula (1a), general formula (1b) or general formula (1c). The compounds of the invention are positive allosteric α2 and / or α3 GABA, receptor modulators.

A method employing a composition comprising a 2 to 10 base synthetic oligonucleotide sequence selected from the group consisting of (GG)n, (GT)n, a(GT)nb, a(GA)nb, and a(GC)nb, wherein n is an integer between 1 and 3, and a and b are independently either none or one or more As, Cs, Gs, or Ts, or combinations thereof, for modulation of Fas and FasL expression or for modulation of the efficacy of therapeutic agents. The composition is administered to an animal or human with a pharmaceutically acceptable carrier, and optionally with a therapeutic agent, in an amount effective to modulate Fas and FasL expression, to treat the disease, or to modulate efficacy of the therapeutic agent.

A temperature sensing circuit that includes a bandgap voltage generation circuit, a current mirror branch, a variable resistor, a comparator circuit, a control circuit and a temperature determining circuit. The bandgap voltage generation circuit generates a bandgap voltage. The current mirror branch generates a mirrored current mirrored from the bandgap voltage generation circuit. The variable resistor is electrically coupled to the current mirror branch to receive the mirrored current to generate a variable voltage. The comparator circuit compares the bandgap voltage and the variable voltage to generate a comparison result. The control circuit generates a control signal according to the comparison result to adjust the resistance of the variable resistor and outputs a signal value when the signal value forces the variable voltage to be equal to the bandgap voltage. The temperature determining circuit generates a temperature value according to the signal value.

The invention relates to methods for high-throughput screening for compounds that modulate cell growth or promoter activity. The invention provides the use of cell lines with properly regulated promoter-reporter expression, suitable for high-throughput screening. More particularly, the invention relates to such screening to identify compounds that affect cell growth and / or that modulate the effect of cell cycle arrest on the function of a promoter that is responsive to cell cycle inhibition.